AOD9604 – Premium Fat-Burning Research Peptide

Name: Buy AOD9604 | Fat-Burning Research Peptide GH Fragment 176-191
Availability: InStock

AOD9604 (GH Fragment 176-191) – Lipolytic Research Peptide

AOD9604 is a synthetic peptide fragment derived from amino acids 177-191 of human growth hormone (hGH), commonly known as GH fragment 176-191 . Originally developed by Metabolic Pharmaceuticals in Australia during the 1990s, this anti-obesity peptide was designed to harness growth hormone’s fat-mobilizing properties while avoiding the metabolic complications associated with full-length GH therapy .

AOD9604 selectively targets fat metabolism through beta-3 adrenergic receptor pathways, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation) . Critically, it does not elevate IGF-1 levels or impair glucose metabolism, distinguishing it from full-length growth hormone therapy .

Key Factual Details

Attribute	Detail
Chemical Name	AOD9604 (Anti-Obesity Drug 9604)
Sequence	Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Fragment 176-191 analog)
Molecular Formula	C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular Weight	1815.0 g/mol
CAS Number	221231-10-3
Purity	≥98% (HPLC verified)
Classification	Growth hormone fragment / Lipolytic peptide

Mechanism of Action & Research Applications

Lipolysis Stimulation: AOD9604 activates beta-3 adrenergic receptors in adipose tissue, triggering the release of stored fatty acids for energy utilization . This enhances fat oxidation without stimulating muscle growth or affecting IGF-1 levels.

Lipogenesis Inhibition: The peptide suppresses lipogenic enzymes, reducing the body’s ability to store excess calories as fat .

Research Applications:

Fat Metabolism Studies: Investigating lipolysis and fat oxidation pathways
Obesity Research Models: Exploring metabolic regulation mechanisms
Cartilage & Joint Research: Some studies suggest potential roles in tissue repair
Metabolic Disorder Research: Examining energy expenditure and body composition

Research Parameters

All dosages are for in-vitro research use only and are not intended for human consumption.

Standard Research Protocol :

Dose Range: 250-500 mcg (0.25-0.5 mg) once daily
Administration: Subcutaneous injection into fatty tissue
Timing: Morning, fasted state (8-10 hours overnight fast)
Cycle Length: 8-12 weeks, followed by 4-week break

Reconstitution :

Standard 5 mg vial reconstituted with 2 mL bacteriostatic water
Final concentration: 2.5 mg/mL (2500 mcg/mL)

Storage:

Store lyophilized powder at -20°C
After reconstitution: refrigerate at 2-8°C, use within 28 days

Order AOD9604 Today – Request a quote for your metabolic research project. Available in various pack sizes with Certificate of Analysis. Contact our sales team for bulk pricing and custom synthesis inquiries.